Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 20, keine Gesamtzahl für „section“
Suchtreffer
Begriffe & Kennungen
Benepali · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenBenepali · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenBenlysta · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenBenlysta · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenBenlysta · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenBenlysta · 4.8 · For information on infections observed in paediatric patients with SLE see Paediatric population section below
Eintrag öffnenBenlysta · 4.8 · For information on infections observed in paediatric patients with SLE see Paediatric population section below
Eintrag öffnenBenlysta · 4.8 · For information on infections observed in paediatric patients with SLE see Paediatric population section below
Eintrag öffnenBenlysta · 4.8 · In the lupus nephritis study, patients were receiving a background of standard therapy (see section 5.1) and t
Eintrag öffnenBenlysta · 4.8 · In the lupus nephritis study, patients were receiving a background of standard therapy (see section 5.1) and t
Eintrag öffnenBenlysta · 4.8 · In the lupus nephritis study, patients were receiving a background of standard therapy (see section 5.1) and t
Eintrag öffnenBeovu · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenBeromun · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenBeromun · 4.3 · Pregnancy and lactation (see section 4.6).
Eintrag öffnenBeromun · 4.5 · Concurrent administration of agents likely to cause significant hypotension is not recommended (see section 4.
Eintrag öffnenBesponsa · 4.3 · - Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. - Patients who h
Eintrag öffnenBesponsa · 4.5 · In patients receiving inotuzumab ozogamicin, prolonged QT interval was observed (see section 4.4). Therefore,
Eintrag öffnenBesponsa · 4.5 · No interaction studies have been performed (see section 5.2).
Eintrag öffnenBesponsa · 4.8 · 13 For clinical management of myelosuppression/cytopenias, see section 4.4.
Eintrag öffnenBesponsa · 4.8 · For clinical management of TLS, see section 4.4.
Eintrag öffnen